Conigen Bioscience
@conigen.bsky.social
Conigen Bioscience, based in Worcester, MA, was founded to bridge a critical gap in therapeutic antibody and drug discovery – addressing the limited availability of recombinant proteins that accurately represent native conformational epitopes.
Read our full article on the science behind #Nectin-4 and learn about Conigen's novel nectin-4 #cis-dimer advancing #cancer-research with native #quaternary-conformation: 🔗 bit.ly/40I9LIG
February 4, 2025 at 5:37 PM
Read our full article on the science behind #Nectin-4 and learn about Conigen's novel nectin-4 #cis-dimer advancing #cancer-research with native #quaternary-conformation: 🔗 bit.ly/40I9LIG
What’s unique about #TIGIT? Unlike other immune checkpoints, TIGIT modulates both T and NK cells, presenting new opportunities to tackle resistant #cancers, especially when paired with PD-1 inhibitors. bit.ly/40zDp2P
January 16, 2025 at 3:59 PM
What’s unique about #TIGIT? Unlike other immune checkpoints, TIGIT modulates both T and NK cells, presenting new opportunities to tackle resistant #cancers, especially when paired with PD-1 inhibitors. bit.ly/40zDp2P
Conigen Bioscience has engineered #IFNγR1 dimer #proteins containing the IFNγR1 ectodomain fused with a dimeric motif at the C-terminus to mimic the natural #dimerization process.
www.conigen.com/ifn-gamma-r1...
www.conigen.com/ifn-gamma-r1...
IFNγR1 Dimeric Protein Enhances Receptor/Ligand Binding - Conigen Bioscience
Interferon Gamma Receptor 1 (IFNγR1) is a critical component of the immune system’s response to pathogens and cancer. This protein is essential for recognizing and responding to interferon-gamma (IFNγ...
www.conigen.com
January 16, 2025 at 3:54 PM
Conigen Bioscience has engineered #IFNγR1 dimer #proteins containing the IFNγR1 ectodomain fused with a dimeric motif at the C-terminus to mimic the natural #dimerization process.
www.conigen.com/ifn-gamma-r1...
www.conigen.com/ifn-gamma-r1...
CXCR4, an emerging key therapeutic target. Conigen is developing an innovative #CXCR4 platform for conducting in vivo animal #immunization and in vitro #bioassays. This platform supports research in areas such as #receptorligandinteractions, #drugscreening, and #mechanisticstudies. bit.ly/3ONMzlL
CXCR4: A Critical Player in Cancer, Immunity, and Therapeutic Innovation - Conigen Bioscience
The CXCR4-CMP is stable and bioactive. It can be specifically and potently bound by CXCR4-specific antibody, and more importantly, it can bind to its ligand CXCL12 and HIV-1 envelope glycoprotein.
bit.ly
December 11, 2024 at 7:14 PM
CXCR4, an emerging key therapeutic target. Conigen is developing an innovative #CXCR4 platform for conducting in vivo animal #immunization and in vitro #bioassays. This platform supports research in areas such as #receptorligandinteractions, #drugscreening, and #mechanisticstudies. bit.ly/3ONMzlL
Conigen Bioscience @conigen.bsky.social
·
21m
Did you know that CD4 is more than just a protein marker on T cells? It’s a central player in coordinating our immune response, crucial for combating pathogens and guiding targeted therapies.
bit.ly/4f8zbmS 🔗
December 9, 2024 at 9:51 PM
Conigen Bioscience @conigen.bsky.social
·
21m
Did you know that CD4 is more than just a protein marker on T cells? It’s a central player in coordinating our immune response, crucial for combating pathogens and guiding targeted therapies.
bit.ly/4f8zbmS 🔗
🎉 Our abstract, "Engineered novel bioactive Nectin-4 dimer protein significantly enhances the binding of TIGIT," has been published in the AACC journal as part of the Abstracts: AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research
bit.ly/3ZIOAWA
bit.ly/3ZIOAWA
Abstract A085: Engineered novel bioactive Nectin-4 dimer protein significantly enhances the binding of TIGIT
Abstract. The goals of this study are to: (a) create a novel soluble bioactive Nectin-4 dimer molecule mimicking its native dimer quaternary structure on the cell surface and (b) evaluate the recombin...
bit.ly
December 9, 2024 at 9:24 PM
🎉 Our abstract, "Engineered novel bioactive Nectin-4 dimer protein significantly enhances the binding of TIGIT," has been published in the AACC journal as part of the Abstracts: AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research
bit.ly/3ZIOAWA
bit.ly/3ZIOAWA